دورية أكاديمية
Contrast-enhanced ultrasound for assessing blood flow modulation of hepatocellular carcinoma by hydralazine.
| العنوان: | Contrast-enhanced ultrasound for assessing blood flow modulation of hepatocellular carcinoma by hydralazine. |
|---|---|
| المؤلفون: | Sultan LR; University of Pennsylvania, Department of Radiology., Al-Hasani M; University of Pennsylvania, Department of Radiology., Karmacharya MB; Childrens' Hospital of Philadelphia, Department of Radiology., Cary TW; Childrens' Hospital of Philadelphia, Department of Radiology., Sehgal CM; University of Pennsylvania, Department of Radiology. |
| المصدر: | IEEE International Ultrasonics Symposium : [proceedings]. IEEE International Ultrasonics Symposium [IEEE Int Ultrason Symp] 2022 Oct; Vol. 2022. Date of Electronic Publication: 2022 Dec 01. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: IEEE Country of Publication: United States NLM ID: 101603970 Publication Model: Print-Electronic Cited Medium: Print ISSN: 1948-5719 (Print) Linking ISSN: 19485719 NLM ISO Abbreviation: IEEE Int Ultrason Symp Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Piscataway, NJ : IEEE |
| مستخلص: | Modulating aberrant tumor microvasculature provides unique opportunities for enhancing ultrasound imaging of hepatocellular carcinoma (HCC). This study aims to use contrast-enhanced ultrasound to evaluate the potential of a potent vasodilator, hydralazine, to attenuate blood flow in HCC while enhancing it in the surrounding liver tissue. The "steel effect," where blood flow is diverted from the lesion to the surrounding tissue aims to enhance lesion-tissue contrast. Methods: HCC was induced in six rats by oral ingestion of diethylnitrosamine for 12 weeks. 10 tumors were studied to assess the enhancement in HCC tumors and surrounding tissue. Contrast-enhanced ultrasound images (CEUS) of each tumor were acquired before and after hydralazine injection. The enhancement of images was analyzed for the qualitative and quantitative assessment of HCC enhancement. Peak enhancement (PE) was calculated, representing the maximum signal intensity reached during the transit of the contrast bolus for both the tumor and the surrounding tissue. Intravenous administration of hydralazine significantly reduced CEUS signals in HCC tumors. The visual examination of images showed that the enhancement of tumors dramatically decreased after hydralazine injection. On the other hand, the surrounding tissue showed an increased enhancement. PE for the HCC changed from (71.8 ± 5) pre hydralazine to (28.7± 4.9), a 61.7% reduction after hydralazine injection, p=0.01. Future studies validating the technique in clinical settings for enhancing lesion-tissue contrast may allow physicians greater precision and accuracy in HCC surveillance for early detection of small tumors. |
| References: | Ultrasonography. 2019 Jul;38(3):200-214. (PMID: 31006227) J Med Ultrason (2001). 2020 Apr;47(2):239-255. (PMID: 32170489) Radiol Med. 2010 Aug;115(5):714-31. (PMID: 20082225) Phys Med Biol. 2013 Sep 21;58(18):6447-58. (PMID: 23999099) Ultrasonography. 2017 Apr;36(2):160-169. (PMID: 28145108) Invest Radiol. 2011 Feb;46(2):106-15. (PMID: 20938345) Radiographics. 2017 Nov-Dec;37(7):1994-2017. (PMID: 29131761) Expert Rev Gastroenterol Hepatol. 2017 Apr;11(4):277-279. (PMID: 28162003) Int J Radiat Oncol Biol Phys. 1992;22(3):455-8. (PMID: 1735677) Sci Rep. 2021 Jul 30;11(1):15553. (PMID: 34330960) Ultrasound Med Biol. 2013 Feb;39(2):187-210. (PMID: 23137926) Am J Gastroenterol. 2014 Sep;109(9):1328-47; quiz 1348. (PMID: 25135008) Biology (Basel). 2021 Jan 22;10(2):. (PMID: 33499069) Hepatol Int. 2017 Jul;11(4):317-370. (PMID: 28620797) Eur J Radiol. 2014 Mar;83(3):456-62. (PMID: 24387826) Biomed Res Int. 2015;2015:349172. (PMID: 26090401) World J Gastroenterol. 2008 Mar 21;14(11):1710-9. (PMID: 18350602) World J Gastroenterol. 2014 Apr 7;20(13):3590-6. (PMID: 24707142) Hepatology. 2018 Jan;67(1):358-380. (PMID: 28130846) PLoS One. 2014 Dec 22;9(12):e113586. (PMID: 25532146) |
| معلومات مُعتمدة: | R01 CA204446 United States CA NCI NIH HHS; R01 EB022612 United States EB NIBIB NIH HHS; S10 OD016310 United States OD NIH HHS |
| فهرسة مساهمة: | Keywords: Hepatocellular carcinoma; contrast-enhanced ultrasound; imaging technologies; tumor vasculature |
| تواريخ الأحداث: | Date Created: 20230424 Latest Revision: 20240607 |
| رمز التحديث: | 20240607 |
| مُعرف محوري في PubMed: | PMC10116375 |
| DOI: | 10.1109/ius54386.2022.9958467 |
| PMID: | 37091308 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1948-5719 |
|---|---|
| DOI: | 10.1109/ius54386.2022.9958467 |